Switch theme
Sign up to access all valuation multiples
SD Biosensor Inc is an in vitro diagnostic company. It aims to contribute to the improvement of quality of life through rapid and accurate disease diagnosis. It is researching and developing quick diagnostics, immunodiagnostics, molecular diagnostics, blood glucose monitoring systems for self -testing.
1999
n/a
LTM Revenue $522M
LTM EBITDA $65.5M
$1.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
SD Biosensor has a last 12-month revenue (LTM) of $522M and a last 12-month EBITDA of $65.5M.
In the most recent fiscal year, SD Biosensor achieved revenue of $505M and an EBITDA of -$6.5M.
SD Biosensor expects next 12-month revenue of XXX and NTM EBITDA of XXX
See SD Biosensor valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $522M | XXX | $505M | XXX | XXX | XXX |
| Gross Profit | $522M | XXX | $247M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 49% | XXX | XXX | XXX |
| EBITDA | $65.5M | XXX | -$6.5M | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | -1% | XXX | XXX | XXX |
| EBIT | -$38.7M | XXX | -$39.3M | XXX | XXX | XXX |
| EBIT Margin | -7% | XXX | -8% | XXX | XXX | XXX |
| Net Profit | -$65.3M | XXX | -$71.5M | XXX | XXX | XXX |
| Net Margin | -13% | XXX | -14% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $297M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, SD Biosensor's stock price is KRW 11660 (or $8).
SD Biosensor has current market cap of KRW 1.39T (or $1.0B), and EV of KRW 1.59T (or $1.2B).
See SD Biosensor trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.2B | $1.0B | XXX | XXX | XXX | XXX | $-0.53 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, SD Biosensor has market cap of $1.0B and EV of $1.2B.
SD Biosensor's trades at 2.3x EV/Revenue multiple, and -178.6x EV/EBITDA.
Equity research analysts estimate SD Biosensor's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
SD Biosensor has a P/E ratio of -15.5x.
See valuation multiples for SD Biosensor and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.0B | XXX | $1.0B | XXX | XXX | XXX |
| EV (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | 2.3x | XXX | XXX | XXX |
| EV/EBITDA | 17.6x | XXX | -178.6x | XXX | XXX | XXX |
| EV/EBIT | -29.9x | XXX | -29.4x | XXX | XXX | XXX |
| EV/Gross Profit | 2.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -15.5x | XXX | -14.2x | XXX | XXX | XXX |
| EV/FCF | -47.0x | XXX | 21.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSD Biosensor's last 12 month revenue growth is 9%
SD Biosensor's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
SD Biosensor's rule of 40 is -30% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
SD Biosensor's rule of X is 35% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for SD Biosensor and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | -1% | XXX | XXX | XXX |
| EBITDA Growth | 20% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -30% | XXX | 8% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 35% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 57% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
SD Biosensor acquired XXX companies to date.
Last acquisition by SD Biosensor was XXXXXXXX, XXXXX XXXXX XXXXXX . SD Biosensor acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was SD Biosensor founded? | SD Biosensor was founded in 1999. |
| Where is SD Biosensor headquartered? | SD Biosensor is headquartered in South Korea. |
| Who is the CEO of SD Biosensor? | SD Biosensor's CEO is Mr. Hyo-Geun Lee. |
| Is SD Biosensor publicy listed? | Yes, SD Biosensor is a public company listed on KRX. |
| What is the stock symbol of SD Biosensor? | SD Biosensor trades under 137310 ticker. |
| When did SD Biosensor go public? | SD Biosensor went public in 2021. |
| Who are competitors of SD Biosensor? | Similar companies to SD Biosensor include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of SD Biosensor? | SD Biosensor's current market cap is $1.0B |
| What is the current revenue of SD Biosensor? | SD Biosensor's last 12 months revenue is $522M. |
| What is the current revenue growth of SD Biosensor? | SD Biosensor revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of SD Biosensor? | Current revenue multiple of SD Biosensor is 2.2x. |
| Is SD Biosensor profitable? | Yes, SD Biosensor is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of SD Biosensor? | SD Biosensor's last 12 months EBITDA is $65.5M. |
| What is SD Biosensor's EBITDA margin? | SD Biosensor's last 12 months EBITDA margin is 13%. |
| What is the current EV/EBITDA multiple of SD Biosensor? | Current EBITDA multiple of SD Biosensor is 17.6x. |
| What is the current FCF of SD Biosensor? | SD Biosensor's last 12 months FCF is -$24.6M. |
| What is SD Biosensor's FCF margin? | SD Biosensor's last 12 months FCF margin is -5%. |
| What is the current EV/FCF multiple of SD Biosensor? | Current FCF multiple of SD Biosensor is -47.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
